Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma.

ABSTRACT:

Objective

To characterize modified R-CODOX-M/IVAC-based chemotherapy to lower the severe adverse events in Chinese adult patients with sporadic Burkitt lymphoma.

Methods

We enrolled a retrospective cohort including 123 adult patients with untreated sporadic Burkitt lymphoma from August 2008 to September 2019 at Sun Yat-sen University Cancer Center. We studied a dose-modified and long-course R-CODOX-M/IVAC regimen utilizing a low dose of 1.0 g/m²/cycle cyclophosphamide, 2 g/m²/cycle methotrexate, 4,500 mg/m²/cycle ifosfamide, and 4.0 g/m²/cycle cytarabine. Forty-nine patients with low risk disease underwent 4-6 cycles of dose-modified R-CODOX-M-based chemotherapy. Seventy-four patients with high risk disease underwent 6-8 cycles of

SUBMITTER: Chen M 

PROVIDER: S-EPMC8330526 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature